Pavel Hamet

Director/Board Member at

Bellus Health (Innodia), Inc.

Health Technology

Consumer Services

Finance

Profile

Pavel Hamet was the founder of Prognomix, Inc. (2005) with the title of President, Co-Chief Executive Officer & Director.
Current jobs include Director at Bellus Health (Innodia), Inc., Director at Canadian Institutes of Health Research, Director at Medpharmgene, Inc., Director at Société Francophone Du Diabete since 2010, and Professor at the University of Montréal.
Former jobs include Chairman at Canada Foundation for Innovation, Director at AGC Biologics SpA, Director at BioCapital Investment Advisors, Inc. from 2003 to 2005, Director at Société de développement Angus, and President at Canadian Hypertension Society.
Education includes a doctorate from McGill University (1972) and a doctorate from the University of Charles (1967).

Pavel Hamet active positions

Companies	Position	Start
Bellus Health (Innodia), Inc. Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products	Director/Board Member	-
Canadian Institutes of Health Research Canadian Institutes of Health Research Miscellaneous Commercial ServicesCommercial Services Operates as funding agency for health research activities	Director/Board Member	02/06/2010
University of Montréal University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	-
Société Francophone Du Diabete	Director/Board Member	01/01/2010
Medpharmgene, Inc. Medpharmgene, Inc. Miscellaneous Commercial ServicesCommercial Services Provides commercial physical research services	Director/Board Member	-

All active positions of Pavel Hamet

Former positions of Pavel Hamet

Companies	Position	End
Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications	Founder	13/01/2015
BioCapital Investment Advisors, Inc. BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody.	Director/Board Member	31/12/2005
Société de développement Angus Société de développement Angus Real Estate DevelopmentFinance Engages in development and project management of urban revitalization projects	Director/Board Member	-
Canadian Hypertension Society	President	-
░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░░░░	░░░░░░░░	-

See the detail of Pavel Hamet's experience

Training of Pavel Hamet

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Pavel Hamet's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	13
AGC Biologics SpA AGC Biologics SpA Pharmaceuticals: MajorHealth Technology Provides pharmaceutical development and manufacturing services for protein-based biologics, cells & gene therapies and messenger RNA	Health Technology
BioCapital Investment Advisors, Inc. BioCapital Investment Advisors, Inc. Investment ManagersFinance The fundamental investment objective of BioCapital is to provide investors superior capital appreciation by investing in equity securities of public companies with high growth potential in biotechnology industries. They seek to achieve this fundamental objective by investing in a diversified portfolio of public companies primarily in the following sectors of the biotechnology industry: therapeutics in the fields of cancer, cardiology, infectious diseases, immune system and central nervous system. The firm also invests in companies developing platform technologies in the fields on genomics and proteomics, drug delivery, theranostics, nanotechnology and monoclonal antibody.	Finance
McGill University McGill University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of Montréal University of Montréal Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Bellus Health (Innodia), Inc. Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products	Health Technology
University of Charles University of Charles Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Develops market molecular diagnostic kits for testing of diabetes complications	Health Technology
Canada Foundation For Innovation Canada Foundation For Innovation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment	Miscellaneous
Canadian Institutes of Health Research Canadian Institutes of Health Research Miscellaneous Commercial ServicesCommercial Services Operates as funding agency for health research activities	Commercial Services
Canadian Hypertension Society
Medpharmgene, Inc. Medpharmgene, Inc. Miscellaneous Commercial ServicesCommercial Services Provides commercial physical research services	Commercial Services
Société de développement Angus Société de développement Angus Real Estate DevelopmentFinance Engages in development and project management of urban revitalization projects	Finance
Société Francophone Du Diabete